CVS Health Corp (CVS)
Official siteHEALTHCARE • HEALTHCARE PLANS • NYSE
Market Cap: $114.32B
Last updated: Nov 17, 2026 at 11:04 AM ET
CVS Health Corp (CVS) Stock Forecast
Analysts expect CVS Health (CVS) to earn $8.28 per share in the fiscal year ending Dec 31, 2026, on revenue of $421.84B. Of 27 analysts, 25 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 13 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 27 ratings average 1.81, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 93% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 7 | 25.9% |
| Buy | 18 | 66.7% |
| Hold | 2 | 7.4% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 27
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 4.8% and revenue estimates rise 2.1%.
- Fiscal year ending Dec 31, 2026
- $8.28
- EPS consensus, revenue $421.84B
- Fiscal year ending Dec 31, 2027
- $8.68
- EPS consensus, revenue $430.79B
- Next report
- Feb 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $8.28 | $8.07 to $8.51 | 22 | $421.84B | $414.39B to $430.68B | 22 |
| Dec 31, 2027 | $8.68 | $8.43 to $9.15 | 26 | $430.79B | $413.32B to $457.62B | 23 |
Quarterly Estimates
The EPS consensus rises from $1.07 for the quarter ending Dec 31, 2026 to $2.74 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.07 | $0.95 to $1.34 | 26 | $109.01B | $102.98B to $121.55B | 22 |
| Mar 31, 2027 | $2.74 | $2.53 to $2.93 | 12 | $101.91B | $97.89B to $104.42B | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 26 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 13 | 0 |
| Fiscal year ending Dec 31, 2027 | 11 | 1 |
| Quarter ending Mar 31, 2027 | 2 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 4.2% from $7.95.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $8.28 | $8.22 | $8.04 | $8.02 | $7.95 | +4.1% |
| Fiscal year ending Dec 31, 2027 | $8.68 | $8.61 | $8.54 | $8.52 | $8.50 | +2.1% |
| Quarter ending Mar 31, 2027 | $2.74 | $2.74 | $2.69 | $2.69 | $2.71 | +1.3% |
Frequently Asked Questions About CVS
What is the CVS stock forecast?
Consensus analyst estimates put CVS Health's EPS at $8.28 for the fiscal year ending Dec 31, 2026, on revenue of $421.84B. The consensus rating from 27 analysts is Buy.
How do analysts rate CVS stock?
Of 27 analysts covering CVS Health, 7 rate it Strong Buy, 18 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CVS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $8.28, with estimates from $8.07 to $8.51 from 22 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $8.68, with estimates from $8.43 to $9.15 from 26 analysts.
What revenue do analysts expect from CVS Health next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $421.84B, with estimates from $414.39B to $430.68B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $430.79B, with estimates from $413.32B to $457.62B.
How many analysts cover CVS?
27 analysts rate CVS Health stock, and 22 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CVS pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts